MedPath

Jubilant Cadista Pharmaceuticals Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

36

FDA:36

Drug Approvals

Olanzapine

Approval Date
Mar 27, 2025
FDA

olmesartan medoxomil

Approval Date
Mar 23, 2025
FDA

NITROFURANTOIN (monohydrate/macrocrystals)

Approval Date
Feb 19, 2024
FDA

valacyclovir hydrochloride

Approval Date
Aug 30, 2023
FDA

Losartan Potassium and Hydrochlorothiazide

Approval Date
Aug 15, 2023
FDA

Spironolactone

Approval Date
Apr 3, 2023
FDA

Loperamide Hydrochloride

Approval Date
Mar 16, 2023
FDA

Risperidone

Approval Date
Feb 24, 2023
FDA

IRBESARTAN

Approval Date
Jun 23, 2022
FDA

IRBESARTAN

Approval Date
Jun 23, 2022
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.